BGPT: Paper Review: Bokhman Redux: Endometrial cancer “types” in the 21st century

Explore by Goal

Quick Explanation Copied

Bokhman Redux—main scientific tension

The paper argues that the classic Type I vs Type II framing—originally proposed as pathogenetic categories—has drifted into a histology-only dualism, which misclassifies biologic substructure (e.g., grade-3 endometrioid, FIGO 3 endometrioid, clear cell) and breaks down against molecular + epidemiologic evidence.

Long Explanation

Paper Review (Visual): Bokhman Redux: Endometrial cancer “types” in the 21st century

DOI: 10.1016/j.ygyno.2016.12.010

Evidence source note: The provided full-text excerpt contains multiple quantitative statements (e.g., Tables 1–3) and a narrative synthesis of molecular/epidemiologic literature; all such claims below are restricted to what is explicitly present in the provided text unless otherwise cited.

Core claim being tested

The paper’s main critical target is categorical dualism—that Bokhman's original pathogenetic grouping has been reinterpreted as an oversimplified Type I/Type II histologic dichotomy, which then generates conceptual and operational errors when modern molecular heterogeneity is considered.

Figure 1 — Pathogenetic types: grade composition (from Table 2)

The percentages come directly from the paper’s Table 2: Lower grade (G1+G2) and High grade (G3) under pathogenetic types I and II.

Figure 2 — Invasion depth and prognosis markers (paper-reported summaries)

Deep vs superficial myometrial invasion percentages and lymph node metastasis prevalence are explicitly stated in the text (not just Table 2).

Figure 3 — Survival by pathogenetic type (from Table 3)

Survival alive (%) for 5-year and 10-year follow-up come from Table 3 (the paper reports both n and alive percentages).

Figure 4 — Concept graph: how dualism can break operationally

A logic map of the paper’s argument structure (what fails when Type I/II is treated like a simple dualism).

This diagram is a distilled representation of the paper’s stated challenges to dualism: grade-3 overlap/molecular ambiguity, clear cell mismatch, mismatch in background endometrium, diagnostic reproducibility problems, and mixed/dedifferentiated tumors not fitting a binary scheme.

What the paper does well (what is strongly supported by its own provided data)

Anchors its critique in quantitative contrasts: It reproduces and relies on Bokhman-style separation for grade, invasion depth, lymph node metastasis prevalence, and survival (Tables 2–3).
Distinguishes “pathogenetic” origin from “histologic” labeling: It explicitly argues that modern usage often collapses these distinctions, creating a definitional error that matters for downstream epidemiology/registry work.

Scientific skepticism: where the argument could be fragile

Historical observational origins vs modern validation: The paper heavily critiques the drift of a paradigm but the excerpt provided does not include new statistical re-estimation of predictive performance; it is largely a narrative synthesis. (This is not automatically wrong, but it is epistemically weaker than revalidation.)
Taxonomic operational ambiguity remains: Even the modern counter-models (molecular groups) can create new definitional boundaries. The paper warns WHO classification restricts 'Type I' in a way that may still leave gray areas (e.g., FIGO 2 and FIGO 3 endometrioid). This implies that merely switching labels does not automatically solve oversimplification.
Confounding/measurement mismatch risk in epidemiology: The paper explicitly notes that correspondence between histology, obesity, and metabolic syndrome is less than perfect, and that background non-neoplastic endometrium may correlate with more aggressive behavior. That means “Type” labels can be entangled with measurement processes (e.g., sampling, staging, and pathology assessment).

What would disprove the paper’s central direction?

Demonstrate that a carefully defined Type I/II framework (with explicit operational rules) predicts outcomes at least as well as modern molecular/pathologic integration—across the tumor subgroups the paper flags as problematic (grade-3 endometrioid, FIGO 3 endometrioid, clear cell, mixed/dedifferentiated).
Reproducibility check: The paper stresses that diagnostic reproducibility for high-grade tumors is suboptimal. If improved pathology standardization restored the mapping to a workable two-class system, that would challenge the critique.

Buttons: go to author-specific BGPT reviews

Feedback:

Updated: May 01, 2026